BioSpace News Archive

Y-mAbs Therapeutics, Inc. announced the acceptance of four abstracts at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Thursday, May 2, 2024.

Scilex Holding Company announced the closing of its previously announced registered direct offering of an aggregate of 15,000,000 shares of its common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 15,000,000 shares of common stock, at a purchase price of $1.00 per share of common stock and accompanying warrant to purchase one share of common stock.

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024.

Stevanato Group S.p.A. announced that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. on Thursday, May 9, 2024, to discuss financial results.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024.

GENFIT, a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, announced the publication of its 2024 Extra-Financial Performance Report.

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.

ARCA biopharma, Inc. reported first quarter 2024 financial results and provided a corporate update.

DBV Technologies will hold its Combined General Meeting on May 16, 2024, at 10:00 a.m. CET at the Company’s new headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France.